Supportive care in oncology is a broad term that encompasses indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. It is a field that has historically been given low priority by physicians, healthcare institutions and pharmaceutical developers alike, and as such, contains various unmet needs.

The figure below presents an overview of the competitive landscapes of six prominent indications within the supportive care in oncology field. Of these six indications, the chemotherapy-induced indications – nausea and vomiting, neutropenia, and anemia – are currently most well-served in terms of available marketed agents.

However, the marketed landscape for oral mucositis is lacking, while cancer cachexia contains a non-existent market landscape as there are no approved treatments for this condition. As such, those two indications present with the highest level of unmet need, and possess high- and medium-sized late-stage pipeline landscapes, respectively.

Chemotherapy-induced neutropenia also possesses a large pipeline, which contains a large number of biosimilars. Various unmet needs also remain in the remaining indications and present numerous opportunities for developers to enter, or expand their presence within, this field by addressing the gaps in these markets.

Competitive landscape across supportive care indications

Source: GlobalData. High, medium and low measurements are provided for each indication relative to the other indications. For example, the late-stage pipelines of oral mucositis and chemotherapy-induced neutropenia are large only in relation to the other indications within this table, rather than being large in terms of the overall oncology field. 

Related reports

GlobalData (2017). PharmaFocus: Supportive Care in Oncology, GDHC010PFR